Benitec Biopharma Inc. (BNTC) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$11.8M

EPS$-0.48

Market Cap$380.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Jerel Banks

CEO & Executive Director

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Founded: 1995
Employees: 19
Headquarters: Hayward, California, United States

⚡

Core Efficiency

ROE?

-6.32%

ROA?

-6.21%

D/E Ratio?

0.02

📊

Profitability Ratios

Current Ratio?

67.69

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jun 10, 2026 (in 62 days)

Quarterly Report (10-Q) — Based on filing pattern

Jun 10, 2026

Predicted10-Q

Feb 12, 2026

10-QQ2 20266d after period end

Nov 14, 2025

10-QQ1 20260d after period end

Mar 20, 2026

10-K/AQ4 2025184d after period end

Sep 22, 2025

10-KFY 202584d after period end

May 14, 2025

10-QQ3 20250d after period end

Feb 14, 2025

10-QQ2 20240d after period end

Nov 14, 2024

10-QQ1 20252d after period end

Sep 26, 2024

10-KQ4 20249d after period end

Loading company sections...

Benitec Biopharma Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness